PXR: a center of transcriptional regulation in cancer.
10.1016/j.apsb.2019.06.012
- Author:
Yaqi XING
1
;
Jiong YAN
2
;
Yongdong NIU
1
Author Information
1. Department of Pharmacology, Shantou University Medical College, Shantou 515041, China.
2. Center for Pharmacogenetics, University of Pittsburgh, PA 15261, USA.
- Publication Type:Journal Article
- Keywords:
Cancer;
NR1I2;
Nuclear receptor;
PAR;
PXR;
Signaling;
Transcriptional regulation
- From:
Acta Pharmaceutica Sinica B
2020;10(2):197-206
- CountryChina
- Language:English
-
Abstract:
Pregnane X receptor (PXR, NR1I2) is a prototypical member of the nuclear receptor superfamily. PXR can be activated by both endobiotics and xenobiotics. As a key xenobiotic receptor, the cellular function of PXR is mostly exerted by its binding to the regulatory gene sequences in a ligand-dependent manner. Classical downstream target genes of PXR participate in xenobiotic responses, such as detoxification, metabolism and inflammation. Emerging evidence also implicates PXR signaling in the processes of apoptosis, cell cycle arrest, proliferation, angiogenesis and oxidative stress, which are closely related to cancer. Here, we discussed, in addition to the characterization of PXR , the biological function and regulatory mechanism of PXR signaling in cancer, and its potential for the targeted prevention and therapeutics.
